A comprehensive system characterisation was performed of the Eckert & Ziegler BEBIG GmbH MultiSource High Dose Rate (HDR) brachytherapy treatment unit with an (192)Ir source. The unit is relatively new to the UK market, with the first installation in the country having been made in the summer of 2009. A detailed commissioning programme was devised and is reported including checks of the fundamental parameters of source positioning, dwell timing, transit doses and absolute dosimetry of the source. Well chamber measurements, autoradiography and video camera analysis techniques were all employed. The absolute dosimetry was verified by the National Physical Laboratory, UK, and compared to a measurement based on a calibration from PTB, Germany, and the supplied source certificate, as well as an independent assessment by a visiting UK centre. The use of the 'Krieger' dosimetry phantom has also been evaluated. Users of the BEBIG HDR system should take care to avoid any significant bend in the transfer tube, as this will lead to positioning errors of the source, of up to 1.0 mm for slight bends, 2.0 mm for moderate bends and 5.0 mm for extreme curvature (depending on applicators and transfer tube used) for the situations reported in this study. The reason for these errors and the potential clinical impact are discussed. Users should also note the methodology employed by the system for correction of transit doses, and that no correction is made for the initial and final transit doses. The results of this investigation found that the uncorrected transit doses lead to small errors in the delivered dose at the first dwell position, of up to 2.5 cGy at 2 cm (5.6 cGy at 1 cm) from a 10 Ci source, but the transit dose correction for other dwells was accurate within 0.2 cGy. The unit has been mechanically reliable, and source positioning accuracy and dwell timing have been reproducible, with overall performance similar to other existing HDR equipment. The unit is capable of high quality brachytherapy treatment delivery, taking the above factors into account.
[1]
N. Sahoo.
Measurement of transit time of a remote after-loading high dose rate brachytherapy source.
,
2001,
Medical physics.
[2]
Patrick N. McDermott,et al.
100 Acceptance testing and commissioning of a new model HDR afterloader
,
1996
.
[3]
P. Johnston,et al.
Transit dose of an Ir-192 high dose rate brachytherapy stepping source.
,
2001,
Physics in medicine and biology.
[4]
B. Thomadsen,et al.
The transit dose component of high dose rate brachytherapy: direct measurements and clinical implications.
,
1993,
International journal of radiation oncology, biology, physics.
[5]
J. Williamson,et al.
Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
,
2004
.
[6]
E. Podgoršak,et al.
High dose-rate brachytherapy source position quality assurance using radiochromic film.
,
2007,
Medical dosimetry : official journal of the American Association of Medical Dosimetrists.
[7]
Wallace Ab,et al.
Acceptance testing, commissioning and quality assurance for a 370 GBq 192Ir HDR brachytherapy afterloader.
,
1997
.
[8]
F Ballester,et al.
Monte Carlo study of the dose rate distributions for the Ir2.A85-2 and Ir2.A85-1 Ir-192 afterloading sources.
,
2008,
Medical physics.
[9]
Asa Carlsson Tedgren,et al.
Audit on source strength determination for HDR and PDR (192)Ir brachytherapy in Sweden.
,
2008,
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10]
J F Williamson,et al.
Code of practice for brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group No. 56. American Association of Physicists in Medicine.
,
1997,
Medical physics.
[11]
D. Wilkinson.
High dose rate (HDR) brachytherapy quality assurance: a practical guide
,
2006,
Biomedical imaging and intervention journal.